ANTIDNA ANTIBODIES FROM AUTOIMMUNE MICE ARISE
BY CLONAL EXPANSION AND SOMATIC MUTATION

By M. Shlomchik, M. Mascelli, H. Shan, M. Z. Radic, D. Pissetsky,*
A. Marshak-Rothstein,† and M. Weigert

From the Institute for Cancer Research, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111;
the *Division of Rheumatic and Genetic Diseases and Immunology, Duke University Medical Center,
Durham, North Carolina 27705; and the †Department of Microbiology, Boston University
Medical Center, Boston, Massachusetts 02215

Systemic autoimmune diseases, such as systemic lupus erythematosus (SLE)¹ in
humans, are characterized by abnormal immune recognition and destruction of mul-
tiple organs and tissues. The immune defect appears to involve both T and B cells,
although the nature of the primary disturbance(s) that ultimately leads to loss of
immunologic self-tolerance is unknown. Many of the systemic autoimmune diseases
are accompanied by serological evidence of autoimmunity in the form of circulating
antibodies to tissue and blood macromolecules (1-3). The presence of various au-
toantibodies is specific for disease, and certain autoantibodies are diagnostic of par-
ticular autoimmune syndromes (2, 3). The titers of some types of autoantibodies,
for example anti-IgG (rheumatoid factors [RF]) in rheumatoid arthritis (4, 5) and
antibodies to dsDNA in SLE (1, 6), correlate with disease activity. Anti-DNA in
particular have been implicated in pathogenesis by direct evidence of DNA-anti-DNA
complexes in diseased kidney (6, 7), as well as evidence that injected anti-DNA is
nephritogenic (8, 9). Understanding what causes the production of autoantibodies
should provide insight into the cause of the disease itself.

We have exploited the MRL/lpr mouse model for SLE to study the etiology of
humoral autoimmunity. Disease in this strain is dependent on the recessive lpr gene
and unknown background genes (10, 11). Although the MRL/lpr syndrome is different
from human SLE in that the lpr gene causes proliferation of an unusual subset of
T cells (12), MRL/lpr disease is strikingly similar in a number of aspects to human
disease. These mice develop multi-system autoimmunity, including a lupus-like
nephritis (11), arthritis (13) and antinuclear antibodies, antibodies to ribonucleoprote-
ins (14), and antibodies to ssDNA and dsDNA (15).

The study of somatic cell hybrids formed with unmanipulated spleen cells from
MRL/lpr mice has recently allowed us to address the question: is the stimulus for

This research was supported by grants from the National Institutes of Health (CA-06927, GM-20964,
and CA-09035) and from an appropriation from the Commonwealth of Pennsylvania. Dr. Mascelli receives
research funds from the Cancer Research Institute, Herman Vander Berg Fellowship.

Address correspondence to Martin Weigert, Institute for Cancer Research, Fox Chase Cancer Center,
7701 Burholme Avenue, Philadelphia, PA 19111.

¹ Abbreviations used in this paper: CDR, complementarity determining region; R, replacement; RF,
rheumatoid factor; SLE, systemic lupus erythematosus.
production of autoantibodies nonspecific polyclonal B cell activation or specific (auto)antigen-driven B cell activation? The advantage of the cell hybridization approach is that it captures both specifically and nonspecifically activated spleen cells; antigen-activated B cells captured in this way have been shown to accurately reflect the humoral immune response (16), and panels of hybrids from polyclonally activated B cells are indeed polyclonal (17, 18). Recently, we showed that the V gene sequences and rearrangements of spontaneous monoclonal RFs from MRL/lpr mice were the product of specific B cell activation mediated via the antigen receptor (19).

We now present a similar analysis of a classical SLE autoantibody: anti-DNA. This analysis shows that anti-DNA, like RFs, are oligoclonal and are the result of specific receptor-driven stimulation, providing strong evidence that this is the case for MRL/lpr autoimmunity in general. Furthermore, knowledge of both V region sequences and antibody specificities shows that: (a) somatic mutations can give rise to the disease-specific anti-dsDNA and that such mutations are selected for; (b) arginine residues play an important role in determining specificity; and (c) antiidiotypes that recognize the majority of anti-DNA are probably not specific for any one family of V regions. These results have important implications for both etiology and therapy of autoimmunity.

Materials and Methods

Antibodies. All mAbs were derived from fusions of spleen cells from MRL/lpr mice (obtained from The Jackson Laboratory, Bar Harbor, ME) with myeloma cell lines. The generation and initial characterization of antibodies from mouse 1 and 2 were described previously (20, 21). Hybridomas from mouse 3 (28 wk of age) were prepared according to the procedure of Marshak-Rothstein et al. (22). Half of the spleen cells were fused with the cell line SP2/0, the other half with Ag8. Somatic cell hybrids from mice 4 and 5 were generated according to the technique of Oi and Herzenberg (23), using the myeloma cell line NS1 as the fusion partner. Mouse 4 was 14 wk old and mouse 5 was 21 wk old. Hybridoma supernatants were screened for antibodies to denatured calf thymus DNA by an ELISA, as described (24). The frequency of anti-DNA hybridomas was 0.19 and 0.06 for mouse 3 and 4, respectively. The frequency was not determined for the other mice. Cells from randomly selected positive wells were cloned twice by limiting dilution. The H and L chain isotypes of the anti-DNA mAbs were determined using subclass-specific reagents (Litton Bionetics, Charleston, SC).

Specificity Analysis. Tissue culture supernatants of each antibody were collected at midlog phase of growth and stored at 4°C with 0.02% NaN3. The concentration of antibody in the supernatants was determined by ELISA, using the following purified myeloma proteins as standards. FLOPC/21 (IgG3) was purchased from Sigma Chemical Co. (St. Louis, MO). The myeloma cell lines 7043 (IgG2a), 2413 (IgG2b), 7210 (IgG1), and 3741 (IgM) (25), were maintained in this laboratory and purified from ascites fluid by standard column chromatography methods.

A standard direct binding ELISA (26) was used to determine mAb binding to ssDNA. A novel assay was used to assess antibody binding to both ss- and dsDNA in solution (Radic, M. Z., and M. Weigert, manuscript in preparation). Briefly, salmon sperm DNA (Sigma Chemical Co.) was purified by treatment with protease and multiple phenol and chloroform extractions, followed by repeated precipitation in ethanol. It was then photobiotinylated using the reagent and protocol of Vector Laboratories, Inc. (Burlingame, CA). From this stock, dsDNA was prepared by treating with SI nuclease, followed by Hae III digestion to yield flush ends. ssDNA was prepared by denaturing dsDNA at 90°C in 10 mM Tris (pH 7.2), 1 mM EDTA for 10 min before dilution in ice-cold PBS-BSA. Dilutions of antibody supernatants in PBS, containing 1% BSA, were incubated with biotinylated DNA (concentration, 2 µg/ml), for 3 h at 37°C. The incubation mixtures were then transferred to microtiter plates that were precoated with 5 µg/ml goat anti-mouse κ antibody (Fisher Biotech, Fair Lawn,
After a 2-h incubation at 37°C, the plates were washed twice with PBS, containing 0.05% Tween 20. Alkaline phosphatase-conjugated streptavidin (Fisher Biotech) was then added according to the recommended dilution, and incubated for 30 min at 37°C. The plates were again washed twice before the addition of a 1% paranitrophenyl phosphate solution in 50 mM NaHCO₃, 10 mM MgCl₂; pH 9.6. Relative binding affinities were determined by calculating the concentration of antibody that generated half-maximum absorbance at 405 nm for both denatured and native DNA. The data (Table II) is represented as the ratio of the half-maximal concentration of native dsDNA over ssDNA. To establish the validity of this assay, two anti-DNA mAbs, H241 and C11, were used as standards because their specificities for dsDNA and ssDNA have been well characterized. H241 recognizes both dsDNA and ssDNA (27), whereas C11 is specific just for ssDNA (24). In this assay, H241 bound to both forms of DNA. C11 bound to ssDNA and showed no significant binding to dsDNA, even at antibody concentrations 30-fold higher than the concentration to achieve half-maximal ssDNA binding.

Oligonucleotides. Oligonucleotides complementary to the 5' border of the mRNA encoding the C regions of the H and k isotypes were synthesized on an oligonucleotide synthesizer (Applied Biosystems, Inc., Foster City, CA). These were purified by electrophoresis through 20% polyacrylamide, 7 M urea gels, followed by absorption to Sep-Pak C18 cartridges (Waters Associates, Milford, MA), and elution in 20% acetonitrile. Sequences of oligonucleotides complementary to the μ, γ1, and κ, and crosscomplementary to γ1, γ2a, and γ2b, C regions used were as previously reported (28, 29). The Jκ1 probe (sequence 5'TGATTTCCAGCTTC-CTGCCTCCAC3'), was a gift from Dr. Andrew Caton (Wistar Institute, Philadelphia, PA).

RNA Isolation and Nucleotide Sequencing. The majority of the V regions were sequenced by synthesizing cDNA from poly(A)⁺ RNA using oligonucleotide primers labeled with 3²P at the 5' end. cDNA was purified and sequenced by a rapid chemical degradation technique, as described by Shlomchik et al. (29). The Vκ and Vκ regions of hybridomas DP7 and DP11 and the Vκ regions of DP12 and DP12 were sequenced directly from the poly(A)⁺ RNA template by the oligonucleotide-primed deoxy chain termination method according to Geliebter et al. (30). The nucleic acid sequences were compared with Ig sequences stored in the EMBL/GenBank Data Libraries.

Results

The Anti-DNA Response in MRL/lpr Mice Is Oligoclonal. The Vκ and Vκ regions of 31 anti-DNA mAbs from five MRL/lpr mice were sequenced and the results are shown in Table I, which summarizes the Vκ, Dκ, Jκ, Vκ, and Jκ segments used. The data show that for each mouse, most antibodies can be grouped into one or more sets, based on their use of the same or highly similar Vκ and Vκ genes. For instance, all antibodies from mouse 1 (set A), two from mouse 2 (set B), five from mouse 3 (set C), and five from mouse 4 (set D) are coded for by Vκ and Vκ genes, which are 98-100% homologous. Mouse 5 is more complex, with three such sets (E, F, and G).

Use of the same V gene pairs among antibodies of individual mice, but rarely between mice, suggests that antibodies of a set are derived from a single B cell precursor. This possibility was borne out by more detailed analysis of the sequences of the third complementarity determining region (CDR3) of Vκ and the rearranged Vκ and Vκ alleles. Because of nucleotide addition (31) and deletion during VDJ joining, the nucleotide sequence in the CDR3 of the H chain is highly variable, even among antibodies with specificity for the same hapten (32; T. Manser, personal communication). Identity of CDR3 nucleotide sequence from unrelated B cells is very unlikely (see Appendix). As shown in Table I and Fig. 1, members of a set defined by identical Vκ, Dκ, and Jκ segment usage had identical Vκ CDR3 sequences as
### Table I

**Summary of Sequence Data of Anti-DNA-producing Hybridomas**

| Mouse | Cell | Clone | Isotype | V<sub>k</sub> group | J<sub>k</sub> | V<sub>u</sub> family | D<sub>u</sub> | J<sub>u</sub> | CDR3 |
|-------|------|-------|---------|---------------------|----------|---------------------|--------|--------|------|
| 1     | A    | 1A11  | IgG2b   | 4                   | 4         | J558                | 2,5,7  | 4      | 11   |
| 1     | A    | 4H8   | IgG2b   | 4                   | 4         | J558                | 2,5,7  | 4      | 11   |
| 1     | A    | 2F2   | IgG2b   | 4                   | 4         | J558                | 2,5,7  | 4      | 11   |
| 1     | A    | 3H9   | IgG2b   | 4                   | 4         | J558                | 2,5,7  | 4      | 11   |
| 2     | O    | 6O    | IgG2a   | 9                   | 1         | Vgam3               | SP 2/SP 2-7 | 4 | 11 |
| 2     | P    | 6P    | IgG1    | 12,13               | 2         | ND                 | ND    | ND     | ND   |
| 2     | N    | 6N    | IgG2a   | 24                  | 2         | J558                | SP 2/FL 16-1 | 2 | 9 |
| 2     | Q    | 6Q    | IgG2a   | 24                  | 2         | J558                | SP 2/FL 16-1 | 2 | 9 |
| 3     | S    | 5C    | IgG3    | 8                   | 5         | J558                | Q 52   | 2      | 11   |
| 3     | S    | 54   | IgG3    | 8                   | 5         | J558                | Q 52   | 2      | 11   |
| 3     | S    | 57   | IgG3    | 8                   | 5         | J558                | Q 52   | 2      | 11   |
| 3     | S    | 204  | IgG3    | 8                   | 5         | ND                 | ND     | ND     | ND   |
| 3     | S    | S106  | IgG3    | 24                  | 4         | 7183                | SP 2-5,7,8 | 3 | 11 |
| 3     | D    | D23   | IgM     | 2                   | 1         | J558                | FL 16-2 | 3 | 8 |
| 3     | D    | D20   | IgG2a   | 8                   | 5         | J558                | FL 16-2 | 3 | 12 |
| 4     | E    | 1E-81 | IgG2a   | 1                   | 2         | J558                | FL 16-1 | 3 | 9 |
| 4     | E    | 3E12  | IgG1    | 31*                 | 2         | 7183                | SP 2-5,7 | 1 | 10 |
| 4     | E    | 6G6   | IgG1    | 31*                 | 2         | 7183                | SP 2-5,7 | 1 | 10 |
| 4     | E    | 3G9   | IgG1    | 31*                 | 2         | 7183                | SP 2-5,7 | 1 | 10 |
| 4     | E    | 2E3   | IgG1    | 31*                 | 2         | 7183                | SP 2-5,7 | 1 | 10 |
| 4     | E    | 6B8   | IgG1    | 31*                 | 2         | 7183                | SP 2-5,7 | 1 | 10 |
| 5     | D    | DP1   | IgM     | 1                   | 2         | S107                | SP 2/SP 2-5,7,8 | 3 | 4 |
| 5     | D    | DP12  | IgM     | 23                  | 2         | 7183                | SP 2-3,4,5,6,7 | 2 | 7 |
| 5     | D    | D7    | IgG3    | 9                   | 1         | J558                | SP 2-8  | 3 | 6 |
| 5     | D    | DP11  | IgG3    | 9                   | 1         | J558                | SP 2-8  | 3 | 6 |
| 5     | D    | D15   | (E)    | ND                 | 9         | 1                   | ND     | ND     | ND   |
| 5     | D    | D17   | F      | 19                  | 1         | J558                | FL 16-2 | 3 | 11 |
| 5     | D    | D9    | F      | 19                  | 1         | J558                | FL 16-2 | 3 | 11 |
| 5     | D    | D13   | G      | 8                   | 5         | ND                 | ND     | ND     | ND   |
| 5     | D    | D18   | (G)    | ND                 | 8         | 5                   | ND     | ND     | ND   |

Hybrids were assigned to clones according to the criteria outlined in the text. Clone names are not given for cells without siblings. Clone assignments of DP15 and DP17 are in parentheses to indicate they are based on \( \kappa \) chain sequence only; no \( \lambda \) sequence was obtained. \( \lambda \) and \( \kappa \) assignments to homology groups are made based on >80% sequence homology to known prototypes. The nomenclature for \( \lambda \) group numbers is as described by Potter et al. (39), and for \( \lambda \) families by Brodeur and Riblet (33), except that Vgam3.8 is the name given to a family of \( \lambda \) genes identified by Winter et al. (34). \( \lambda \) designations are by homology to the closest known BALB/c gene (46). The CDR3 length is defined as the number of amino acids between the last amino acid encoded by \( \lambda \) genes (two residues after the invariant cysteine) and the invariant tryptophan residue encoded by all \( \lambda \)s.

* This \( \lambda \) sequence does not meet the criteria for assignment to a known \( \lambda \) group (39). We therefore assign it to a new \( \lambda \) group, 31.
Figure 1. Legend on page 273.
**Figure 1.** Continued.
Figure 1. Continued.
Figure 1. Continued.
well. This criterion alone makes it unlikely that members within a set are independently derived. Even using a conservative model system (the highly restricted response to p-azophenylarsonate) and conservative statistical assumptions, we find the chance of two unrelated B cells having identical CDR3 nucleotide sequences is 0.067 and the chance of three unrelated B cells sharing CDR3 sequence is 0.023 (see Appendix).

Related B cells can also be identified by the context of their unexpressed $V_H$ and $V_L$ alleles if these are not in the germline configuration. Identity of restriction fragment lengths at the unexpressed alleles of unrelated B cells is unlikely (see Appendix). Southern analysis of the H chain alleles of members in sets A, C, D, and E showed that in each case, the majority of hybrids in a putative clone had identical restriction fragment lengths at both alleles, whereas patterns differed between clones (data not shown). In the rest of the members of these clones and in clones B, F, and G, the expected fragment containing the unexpressed allele was absent, which we attribute to segregation of chromosomes after cell fusion. The restriction patterns at the $\kappa$ alleles were uninformative, as all clones either had unrearranged alleles or multiple members that segregated the unexpressed allele.

In summary, the majority of the DNA antibodies in individual mice are members of one or a few clones (Table I), since each set meets at least two of the three criteria for clonal relatedness discussed above. The majority (50-100%) of the DNA antibodies of all five of the MRL/lpr mice are produced by just one or a few clones. These clones must, therefore, have undergone a significant amount of in vivo expansion. Given that hybridization immortalizes $10^3$ to $10^5$ of splenic B cells (16, our unpublished data), even two related hybrids represent clones on the order of $2 \times 10^4$ to $2 \times 10^5$ cells. This analysis also identified six hybridomas that could not be

---

**Figure 1.** Nucleotide sequences of H chain ($V_H$) regions of anti-DNA antibodies. The lettered subparts of the figure show homologous sets of sequences all belonging to the same $V_H$ family, with the exception of $D$, which includes sequences from two $V_H$ families. Sequences that are from clonally related hybridomas (see text) are grouped, followed by a space. Sequences in each subpart are compared with a single prototype (the names of which are underlined), with the exception of $D$, which uses two prototypes. Identities are indicated by dashes. The translation of the prototypes are given above the nucleotide sequence. Spaces are introduced to maximize alignment; a gap is introduced at the end of the V-encoded region (i.e., two codons after the invariant cyst codon) to maximize homology with $J_H$. Spaces at $S$ ends of some sequences indicate that these regions have not been determined. Arginine codons in $V_H$ CDR3 or that result from differences with the consensus or prototype sequence are designated with Arg. The Arg designating codons at position 77 of the $V_H$ of DP7 (AGA) and DP11 (CGC) are marked by an asterisk to indicate that both codons encode arginine. The start of the framework (FR) and CDR (44), are separated by vertical spaces, and the top line of each sequence group gives the name of each subregion (e.g., CDR1 or FR2). A bar has been placed over nucleotides with homology to a known BALB/c germline D gene. Two bars over the same sequence indicate a possible fusion of two D gene segments. The direction of the arrow indicates whether sense or antisense strand of the D gene is translated (see text for details). The sources of prototype sequences are: (A) VH133.16 from a mAb from a C57Bl/6 mouse (43). Gaps in the reported sequence of VH133.16 have been filled with the consensus of all members in the group. These regions are designated with lower case letters. (B) VH31, an NP-like pseudogene from BALB/c (87). Asterisks denote stop codons in its sequence. (C) VH283, a germline gene from the 7183 family (88). (D) 6G6, a rearranged $V_s$ family gene cloned from a CBA hybridoma (89), and pH3-6a, a cDNA clone from C57Bl/6 splenic mRNA (90); the sequence is from the Vgam3 family. In (A), the sequence of 1A11 has been corrected compared with Shlomchik et al. (20). These sequence data have been submitted to the EMBL/GenBank Data Libraries.
assigned to sets with multiple members (i.e., “singlets”). Of course, singlets would 
be found in a small sample of cells from a mouse made up, concurrently, of clones 
of different sizes. Mouse 5, with three clones (of size 3, 2, and 2) illustrates this. 
Thus, a singlet could represent an expanded clone of fewer cells than clones from 
which we have found multiple examples. Alternatively, they could represent cells 
without siblings.

Ig V<sub>H</sub> and V<sub>k</sub> Usage. Ig V gene usage can be interpreted in the context of the 
inherited V gene repertoire of inbred mice. At present, 13 V<sub>H</sub> and 30 V<sub>k</sub> groups 
(based on >80% nucleotide sequences homology) have been identified (33–39). It 
is estimated by Southern hybridization that there are ~125 V<sub>H</sub> and ~150–250 V<sub>k</sub> 
genes (33, 40). Our panel of 31 antibodies (combined with the nine examples de-
scribed by others [36, 41, 42]) shows that anti-DNA antibodies are encoded by at 
least five different V<sub>H</sub> families and 13 different V<sub>k</sub> groups (Table I).

In spite of the V gene diversity among DNA antibodies, certain V gene preferences 
emerge in this extensive survey. A single J<sub>558</sub> V<sub>H</sub> gene is probably used in 
three separate clones. D20, clone A, and clone E are 96% homologous, and closely 
homologous to a V<sub>H</sub> gene, 133.16, described previously (43) (Fig. 1A). The restriction 
fragment length of the rearranged allele in the three clones is the same (ad-
justing for different J<sub>H</sub> usage), also consistent with their utilizing the same V<sub>H</sub> gene 
(data not shown). DNA blotting data with oligonucleotides overlapping the mutations 
at sites 160 and 173 in 3H9 confirms this (Mascelli, M. and M. Weigert, manu-
script in preparation). This V<sub>H</sub> gene is preferentially selected; assuming 100 germ-
line V<sub>H</sub> genes, the likelihood of choosing the same gene three times in 15 samples 
by chance is 0.03. Another possible preference is for V<sub>k</sub>8 in that different members 
of this group are found in 3 of the 15 independently derived sets. This frequency 
would indicate a significant bias (p = 0.05) if the V<sub>k</sub>8 group constituted not >5.7% 
of the V<sub>k</sub> repertoire. However, V<sub>k</sub>8 is thought to comprise at least 10% of the V<sub>k</sub> 
gene repertoire (40), therefore this V<sub>k</sub>8 incidence does not represent a significant bias.

The V<sub>k</sub> of clone D is just 77% homologous to V<sub>k</sub>9 (44), its closest relative, and 
therefore does not meet criteria for assignment to a known V<sub>k</sub> group. We therefore 
assign it a new V<sub>k</sub> group, 31. Finding a new V<sub>k</sub> group in this survey of antibodies 
to a novel antigen does not necessarily mean that this group is uniquely associated 
with the DNA antibodies of the autoimmune mouse, as statistical models predicted 
that six V<sub>k</sub> groups were as yet unidentified (39).

J<sub>H</sub>, D<sub>H</sub>, J<sub>k</sub>, D<sub>k</sub> Usage and Functional Diversity. No restriction to a particular J<sub>H</sub>, J<sub>k</sub>, or 
D<sub>H</sub> segment was seen: all J<sub>H</sub>, J<sub>k</sub> gene segments, as well as representatives from each 
D<sub>H</sub> family, were found (Table I). This variety of gene segment usage leads to con-
siderable phenotypic variation of the V<sub>H</sub> CDR3 of these antibodies, both in amino 
acid composition and length. Two unusual features of anti-DNA V<sub>H</sub> CDR3s, rela-
tive to other antibodies, were noted. One is similar to the observation of Eilat et 
al. (42) that the anti-DNA antibodies A52 and D42 read their D<sub>H</sub> segments in a 
frame different from other antibodies. As noted by Kaartinen and Mäkelä (45), most 
antibodies read D<sub>H</sub> in the same frame. Here, 5 of the 13 independent clones (S106, 
D20, DPl, clone E, and clone F) show a D reading frame shifted one nucleotide 
backward or forward from the preferred reading frame. One interesting consequence 
of this shift is that in three cases (clone E, clone F, and S106), these reading frames 
yield arginine codons.
A second unusual feature of anti-DNA or V₃ CD3s is that fusion of two D segments may have occurred during V₃ assembly. D-D fusion has been previously invoked to explain sequences of CDR3 of other antibodies (18, 46-48). As illustrated in Fig. 1, C and D, for antibodies 60 and DP12, one of the Ds participating in the fusion is inverted relative to the other segments. For 6N (Fig. 1 A) the CDR3 segment is formed by the fusion of two inverted D gene segments. The 5' D segment matches the noncoding strand of the SP2 core sequence in seven of eight nucleotides, and the 3' region matches the noncoding strand of FL16-1 in seven of eight nucleotides. The 5' CDR3 region of 60 is a perfect match of six nucleotides with an SP2 gene segment and the 3' region matches 8 of 10 nucleotides of the noncoding strand of a different D segment. Likewise, the 5' CDR3 region of DP12 is a perfect match of seven nucleotides with an SP2 gene, and at the 3' end, six of seven nucleotides match the noncoding strand of SP2-5, -7, or -8. In two of these three examples, inverted Ds encode arginine residues.

**Somatic Mutation.** As shown in Figs. 1 and 2, there are numerous intraclonal differences, indicative of somatic mutation during clonal expansion. These intraclonal comparisons provide a minimum estimate, because mutations shared by all members of a clone will not be recognized. However, as discussed above for clones A, E, and D20, the likely germline donor V₃ sequence is known, and the exact frequency of mutation can be determined. The comparison of the V₃ genes of clone A to the germline V₃ (Fig. 1 A) reveals a shared mutation not apparent from interclonal comparison. We surmise that this mutation represents an early event in the expansion of this clone. D20, a singlet, is identical to the germline V sequence.

**Specificity Analysis.** Anti-DNA detected by screening hybridoma supernatants for binding to denatured calf thymus DNA were further analyzed by both solid and solution phase DNA binding assays. These assays confirmed the initial screen in that all examples bound denatured ssDNA (20, 21, Table I, and data not shown).

Most members of clones (with certain exceptions discussed below) had indistinguishable binding activities for ssDNA by either assay, for instance, clones C, E, and F (Table II, and data not shown). Interclonal comparisons, on the other hand, showed pronounced differences. This can readily be seen in Table II for ssDNA binding of clones D and F. Since these antibodies are the same H chain isotype, these differences are attributable to V gene sequence. Such interclonal differences are consistent with the high degree of V region diversity between clones.

Interclonal differences in dsDNA binding were also apparent, including several examples for which no dsDNA binding was detectable (Table II). Nevertheless, one or more members of each clone bound dsDNA. Thus, at the levels of hybridomas, this characteristic serologic feature of autoimmunity is also seen. Among the singlets, a clear distinction is seen between the IgM and IgG antibodies. Whereas all IgG singlets bound dsDNA, the IgM singlets only bound ssDNA. In this respect, these IgM antibodies are similar to the anti-DNA seen in normal individuals and may result from a different activation mechanism than the IgG anti-DNA typical of autoimmune disease.

Intraclonal differences are seen for both ds- and ssDNA binding. These differences can only result from somatic mutation, therefore, the structural basis for differences in specificity can be attributed to limited amino acid substitutions. These substitutions often include mutations to arginine or asparagine, amino acids known...
Figure 2. Legend on page 280.
Figure 2. Continued.
Figure 2. Continued.
Figure 2. Continued.
to play a central role in DNA-protein interactions (49, 50). For example, 3H9, a member of clone A, has acquired an additional arginine in CDR2 of its H chain. This arginine could account for the unique ability of this member of clone A to bind dsDNA, as well as to bind ssDNA with higher affinity than the other members of clone A. DP7 and DPII (clone E) both bind dsDNA but differ significantly in affinity. Again, the somatic mutations that must determine this difference include a serine to arginine replacement in CDR1 of the V \( \kappa \) of DPII. However, this mutation did not lead to a significant difference in affinity for ssDNA. Thus, even though arginine has the potential for binding to epitopes unique to dsDNA, as well as epitopes shared by both ds- and ssDNA (such as phosphodiester linkages), the arginine of DPII may be constrained to interact just with dsDNA moieties.

Discussion

MRL/\( \text{lpr} \) mice develop a progressive autoimmune syndrome serologically and pathologically similar to human SLE (2, 10, 11, 14, 51). To examine the B cells that secrete these pathologic autoantibodies, we have constructed hybridomas from unmanipulated splenic lymphocytes of unimmunized older MRL/\( \text{lpr} \) mice. In these mice, the frequency of such spontaneous hybridomas that secrete self-specific antibodies (e.g., anti-dsDNA [this work] and anti-Ig [52]) is much higher than the frequency among preimmune LPS-stimulated B cells of several normal mouse strains (53-55) or unmanipulated B cells of normal C57Bl/6 × DBA/2\( F_1 \) mice (56). We have determined the specificity and V region sequences of monoclonal anti-DNA autoantibodies from five different MRL/\( \text{lpr} \) mice. These data allow us to draw several important conclusions about the mechanism of humoral autoimmunity in MRL/\( \text{lpr} \), the genetic basis of anti-DNA specificity, and the possible structural basis for idiotypes.

Pathologic Anti-DNA Are the Result of Oligoclonal B Cell Expansion

Since the anti-DNA repertoire in a mouse is large (54, 55, 57), a polyclonal activation model would predict a multiclonal response. However, at least half of the hybrids from each of the mice were members of expanded clones. Therefore, the model of autoimmunity that accounts for anti-DNA production via polyclonal activation is inconsistent with our data, and this model does not apply to the MRL/\( \text{lpr} \) syndrome.

Clonal Expansion Is Specific and Receptor Driven

The oligoclonal composition of the anti-DNA from each mouse establishes that the activation and propagation of DNA-specific B cells in MRL/\( \text{lpr} \) mice is selective. Although the selective expansion of certain B cells could be independent of the antigen receptors, our data indicate that for anti-DNA, selection is dependent on receptor specificity. This conclusion comes from features of the genes encoding the receptors.

![Figure 2](image-url)

**Figure 2.** Nucleotide sequences of L chain (V \( \kappa \)) regions of anti-DNA antibodies. The sequences are organized as in Fig. 1. Sequences from the same V \( \kappa \) group as defined by Potter et al. (39) are together. In some cases a prototype and its translation are given; where no prototype is given, the topmost sequence of each homology group is translated. Prototypes are: (A) V \( \kappa 1 \), a BALB/c germline gene from this group (91), and V \( \kappa 41 \), a BALB/c germline gene from the V \( \kappa 9 \) group (92); and (B) H144V \( \kappa 8 \), an mRNA sequence from an influenza hemagglutinin-specific IgM hybridoma expressing the consensus sequence of a V \( \kappa 8 \) group gene (Clarke and Weigert, manuscript submitted for publication), and anti-PC, a consensus from a set of highly homologous sequences from PC-specific antibodies thought to all express a single (different) V \( \kappa 8 \) group gene.
Solution Phase DNA Binding of mAbs

Native and denatured DNA specificity was assayed according to the procedure outlined in Materials and Methods. Triplicate determinations were performed for each concentration of antibody. Antibody concentrations at half-maximal binding are determined by extrapolation from the linear portions of the binding curves. The confidence interval for a value of the independent variable (antibody concentration), based on a single value of the dependent variable, was determined by simple linear regression using the IMSL subroutine RINPF, as discussed by Graybill (86). The IgM antibodies (DP1, DP12, and D23) did not give detectable binding in this assay for either form of DNA. Antibodies IA11, 4H8, and DPI3 showed no significant binding to ssDNA. (>) The highest antibody concentrations assayed for which no binding was detected.

Values for ssDNA and dsDNA are significantly different from other clone members.

The antibody concentrations of supernatants of S41 + S54 were too low to generate binding curves.

Value for dsDNA is significantly different from DP11.

DP11 is unusual because maximal binding to ssDNA was lower than the other antibodies. The epitope on ssDNA recognized by this antibody may be limiting. As we only wish to demonstrate relative binding to ssDNA without regard to the precise epitope, we have normalized the maximum A405 reading of DP11 to that achieved by C11, our standard for maximal ssDNA binding.

H241 is anti-ssDNA and anti-dsDNA (27).

C11 is anti-ssDNA (24).

### Table II

| Mouse | Cell | Clone | 50% Maximal binding | ssDNA | dsDNA | ss/dsDNA |
|-------|------|-------|---------------------|-------|-------|----------|
|       |      |       | µg/ml               |       |       |          |
| 1     | A    | 1A11  | 0.55 ± 0.02         | >1.1  | -     |          |
| 1     | A    | 4H8   | 0.57 ± 0.04         | >4.0  | -     |          |
| 1     | A    | 3H9*  | 0.12 ± 0.01         | 0.32 ± 0.04 | 0.4 |
| 3     | A    | S106  | 2.2 ± 0.20          | 1.55 ± 0.15 | 1.4 |
| 3     | C    | D20   | 0.65 ± 0.07         | 0.43 ± 0.04 | 1.4 |
| 3     | C    | S7    | 2.5 ± 0.60          | 2.3 ± 0.80 | 1.1 |
| 3     | C    | S41*  | ND ND               | -     |          |
| 3     | C    | S54*  | ND ND               | -     |          |
| 3     | C    | S57   | 3.8 ± 1.0           | 3.1 ± 0.20 | 1.2 |
| 4     | A    | 1E81  | 0.03 ± 0.00         | 0.54 ± 0.05 | 0.06 |
| 4     | D    | 3E12  | 0.62 ± 0.04         | 0.34 ± 0.02 | 1.8 |
| 4     | D    | 6G6   | 0.60 ± 0.04         | 0.33 ± 0.06 | 1.8 |
| 4     | D    | 6B    | 0.72 ± 0.05         | 0.52 ± 0.14 | 1.4 |
| 4     | D    | 3G9   | 0.76 ± 0.06         | 0.42 ± 0.06 | 1.8 |
| 4     | D    | 2E3   | 0.71 ± 0.06         | 0.45 ± 0.07 | 1.6 |
| 5     | E    | DP7*  | 0.38 ± 0.03         | 0.58 ± 0.18 | 0.7 |
| 5     | E    | DP11* | 0.34 ± 0.05         | 0.1± ± 0.02 | 2.3 |
| 5     | F    | DP9   | 0.13 ± 0.01         | 0.10 ± 0.01 | 1.3 |
| 5     | F    | DP17  | 0.12 ± 0.01         | 0.09 ± 0.00 | 1.5 |
| 5     | G    | DP13  | 0.07 ± 0.02         | >2.2  | -     |          |
|       | G    | H241  | 1.0 ± 0.20          | 0.90 ± 0.10 | 1.1 |
|       | C11**|       | 0.016 ± 0.02        | >6.0  | -     |          |
### Table III

**Anti-DNA VH CDR3 Amino Acid Sequences**

| Name     | VH family | JH gene | C gene | V<sub>H</sub> CDR3 | J<sub>H</sub> | C<sub>H</sub> |
|----------|-----------|---------|--------|-------------------|-------|-------|
| 60       | Vgam3     | yRRyRyR | mfdy   | 4                 | IgG2a |
| 6N (2)   | J558      | yRRllyp | fay    | 2                 | IgG2a |
| DP9 (2)  | J558      | ngRRR  | awfay  | 3                 | IgG1  |
| MRL22*   | J558      | RlyR   | yamydy | 2                 | IgM   |
| BXW14*   | J558      | BgrtvRd| dy     | 2                 | IgM   |
| D42*     | S107      | gglRggR |
| A52*     | J558      | RlRggg |
| 2E3 (5)  | 7183      | Rdhywwf| fdy    | 1                 | IgG1  |
| 1A11 (4) | J558      | aRskysyv| mdy   | 4                 | IgG3  |
| S57 (5)  | J558      | Rglgkg | yfdy   | 2                 | IgG3  |
| DP7 (2)  | J558      | nR     | wfray  | 3                 | IgG3  |
| S106     | 7183      | ggrRggg| awfay  | 3                 | IgG3  |
| D20      | J558      | sglRglip| fay   | 1                 | IgG2a |
| 1E81     | J558      | Rshy   | awfay  | 3                 | IgG2a |
| BXW7*    | J558      | Rrayyysph| wyfay| 1                 | IgM   |
| H130*    | J558      | aRaysny| yamdy  | 4                 | IgM   |
| D23      | J558      | cRnyyg | fay    | 3                 | IgM   |
| DP1      | S107      | lw     | ay     | 3                 | IgM   |
| DP12     | J558      | lygai  | dy     | 2                 | IgM   |
| MRL10*   | J558      | lvgg   | fay    | 3                 | IgM   |
| MRL4*    | 10        | daanwsa| wfray  | 3                 | IgG2a |

The antibodies in this survey and published anti-DNA sequences are included. Each clone is represented by only one cell line. Numbers in parentheses after the name indicate the total number of hybridomas from that clone; singletons are not given numbers. In the CDR3 column are given the single letter amino acid sequences of V<sub>H</sub>CDR3s (as defined by Kabat et al. [44]). Arginine residues (R) are capitalized and bolded. The portion of the CDR3 sequence encoded by the J<sub>H</sub> region, as inferred by nucleotide sequence homology, is listed to the right, separated from the remainder of CDR3 by spaces. The V<sub>H</sub> family, J<sub>H</sub> gene, and C<sub>H</sub> gene used are given in separate columns; assignments are the same as in Table I. Sequences are listed in order of descending arginine content. The five sequences at the bottom do not contain arginines. MRL22, BXW14, BXW7, MRL10, and MRL4 are taken from Kofler et al. (36); D42 and A52 are from Eilat et al. (42) and H130 is from Trepicchio et al. (41).

* Sequences from other sources.

The antibodies in this survey and published anti-DNA sequences are included. Each clone is represented by only one cell line. Numbers in parentheses after the name indicate the total number of hybridomas from that clone; singletons are not given numbers. In the CDR3 column are given the single letter amino acid sequences of V<sub>H</sub>CDR3s (as defined by Kabat et al. [44]). Arginine residues (R) are capitalized and bolded. The portion of the CDR3 sequence encoded by the J<sub>H</sub> region, as inferred by nucleotide sequence homology, is listed to the right, separated from the remainder of CDR3 by spaces. The V<sub>H</sub> family, J<sub>H</sub> gene, and C<sub>H</sub> gene used are given in separate columns; assignments are the same as in Table I. Sequences are listed in order of descending arginine content. The five sequences at the bottom do not contain arginines. MRL22, BXW14, BXW7, MRL10, and MRL4 are taken from Kofler et al. (36); D42 and A52 are from Eilat et al. (42) and H130 is from Trepicchio et al. (41).

* Sequences from other sources.

Nonrandom Patterns of Somatic Mutation. V regions from antigen-activated B cells have characteristic, nonrandom patterns of somatic mutations (28, 58). These patterns must result from positive selection of cells with R mutations in CDRs, presumably because some of these mutations improve affinity for antigen (32, 59, 60). This process often leads to a population of cells with a higher percentage of R mutations in CDRs than can be explained by chance alone. We find that autoantibodies have similar skewed patterns of mutations: nonrandom mutation is present among multiple clones of RFs derived from autoimmune mice, as we previously reported, and in clone A (19, 20). A nonrandom pattern (p = 0.03, analysis as described in...
Shlomchik et al. (20)) is also found in Clone E. These improbable distributions can be accounted for by selection, but not by receptor-independent stimulation. The other clones shown are uninformative in this regard because we cannot identify enough mutations to permit a meaningful analysis of the distribution.

Specificity for dsDNA. In humans and mice, the preimmune repertoire includes mainly ssDNA-specific B cells and few dsDNA-specific B cells (7, 54, 55). We selected the hybridomas on the basis of ssDNA binding alone. In the absence of preferential in vivo expansion of dsDNA-specific cells (i.e., selection), we would have expected mainly anti-DNA specific for ssDNA only. Instead, most of the antibodies that we recovered recognized both ss- and ds-DNA. As others have noted (61–63), this result (frequent recovery of what is a rare specificity in the preimmune repertoire) can readily be explained by selection for anti-dsDNA. Nonspecific activation models could also explain this observation if a subset of B cells enriched for certain self-specificities (such as dsDNA) were preferentially (but nonspecifically) activated during autoimmunity. However, such a B cell subset model cannot explain our results, since in two separate cases (clones A and E), we have found descendents of a single B cell precursor that differ dramatically in their ability to bind dsDNA. Thus, ds- and ssDNA-specific autoreactive cells can be derived from the same precursor B cell.

Somatic Mutations Can Cause dsDNA Specificity and Are Selected During Clonal Expansion. The differences in specificity among members of clones A and E must be due to somatic R mutations (Figs. 1 and 2). Certain features of these mutations argue for positive selection of mutant receptors. First, somatic mutations in 3149 and DP11 lead to better dsDNA binding. Thus, in at least two cases clones have evolved toward higher affinity for dsDNA. Second, the small number of such mutations that nonetheless caused improvement in affinity for dsDNA suggests that selection for these mutants took place in vivo. We infer this because the number of mutations that can improve affinity is small relative to the number of possible silent mutations, R mutations in conserved sites that destroy antibody function (~35%, [20]) and the fraction of R mutations in CDRs that adversely affect binding. Thus, in an unselected population of cells, each with a few random mutations, as would result from receptor nonspecific activation, antibodies with enhanced binding would be rare. However, selection would enrich for such mutants and could explain the observed pattern of mutations. Third, the nature of individual mutations in these and other clones appears to reflect a predictable consequence of selection by DNA: there is a high frequency of mutations leading to arginine and asparagine residues, amino acids known to play a role in binding to DNA (49, 50). In clone E, of seven total R mutations, there are four independent changes to arginine and one to asparagine. Of the three unique replacement mutations that occurred in 3H9, one (in CDR2) was a change to arginine. Strikingly, in two cases, independent mutations occurred in the same codon of the clone E Vn; two different base changes generated serine to arginine mutations at codon 76 and separate base changes converted serine to arginine in one case and to asparagine in the second case at codon 31 (Fig. 1).

Selection for Arginines Is a Common Feature of Anti-DNA. In addition to finding arginines generated by somatic mutations, we identified arginines at sites where this residue has never or rarely been found in large collections of sequences of other V genes from the same gene families (44, 64, 65). These unprecedented arginines are likely to be the result of somatic mutations. These are the contiguous arginines in VnCDR2 of clone D, position 64 of VnCDR2 of clone B, position 27F of the V
CDR1 of D20, DP13, and DP18, and position 29 of the V<sub>κ</sub>CDR1 of DP13 and DP18. It is of interest that all occur at sites in the combining site.

The V<sub>κ</sub>CDR3s of these antibodies also contain many arginines: out of 339 CDR3 residues, 46 were arginine (among 37 sequences, including the nine sequences from the literature [36, 41, 42]). All but five sequences had one arginine and five had two, four had three, and one had four arginine residues in CDR3 alone. The large pool of known V<sub>κ</sub>CDR3 sequences (as compiled by Kabat et al. [44]) allows a reasonable estimate of the random frequency of arginines in this region, thus making it possible to test whether the arginine content in this region of anti-DNA is significantly higher than expected. There were 105 arginines in 3,066 CDR3 residues in the Kabat et al. compilation. A χ² analysis of the frequency of arginines in the Kabat et al. data and in these anti-DNAs gives a χ² of 76 (1 df, p < 5 x 10⁻⁷).

Unusual mechanisms appear to explain the generation of arginine codons during somatic V region assembly, including out-of-frame D joining and D-D fusion. In addition, some of the arginine codons arise from nontemplated bases (N regions, [31]). Unlike the somatic mutations to arginine that occur during the antigen driven phase of B cell differentiation, the CDR3 arginines were formed at the earlier pre-B cell stage of differentiation, when V assembly occurs. Therefore, the process of selection that resulted in enrichment of arginines in V<sub>κ</sub>CDR3 probably began at or near the beginning of clonal expansion and continued during the phase of accumulation of somatic mutations. Since these V<sub>κ</sub>CDR3 arginines and those formed at later stages by somatic mutation can both be selected, the loss of regulation against self-specificity in MRL/lpr autoimmunity is ongoing, and probably encompasses multiple stages of B cell activation.

The Meaning of Single Isolates

One in four of our hybrids are "singlets," which cannot be assigned to sets with multiple members. Since clonal size cannot be estimated from singlets, they could represent very small clones. If singlets do indeed represent many very small clones, these in turn could result from either polyclonal activation or recent antigen activation. Polyclonal activation could account for the fact that three of the singlets in this study lack the features of selection described above: they are IgM, lack CDR3 arginines, and do not bind dsDNA. On the other hand, the singlets that do have these features may have come from expanded clones from which we isolated just one example.

If in vivo polyclonal activation does lead to autoantibody production, as claimed by Klinman and colleagues (66, 67), our data show that its role is limited in two regards. First, it would have to exert its effect only early in the process of self-specific B cell activation, since the current studies clearly establish that oligoclonal expansion is the proximate event to the development of pathogenic-type IgG autoantibodies. Therefore, any changes in B cell differentiation state due to polyclonal activation would only serve to facilitate this process, perhaps by lowering the threshold for antigen activation or allowing B cells to bypass the usual control(s) over self-recognition. Second, even if all of the single isolates did represent polyclonally activated B cells, their contribution to the pool of DNA-specific activated B cells in older MRL/lpr mice is minor, since they comprise only about one-quarter of all our anti-DNAs and of our RFs (19).
Genetic Control of Anti-DNA Specificity

We have identified several strategies that contribute to DNA binding. Germline V genes must in part encode the ability to bind DNA; although many different V genes are used in anti-DNA, we do not expect that all or even most V genes will be capable of encoding DNA specificity. This is supported by the fact that the representation of V genes in our anti-DNA sample is not entirely random, since at least one V gene is found more frequently among anti-DNA than expected. The frequency of this V suggests it plays a role in DNA binding. However, as some of the antibodies expressing this V bind only ssDNA (e.g., 1A11), while others bind dsDNA, other elements must also contribute. The nature of the V<sub>H</sub>CDR3 sequences, as discussed, strongly implies that this region also plays a role in binding in at least some antibodies. Somatic mutations are another factor, as shown by the two cases of mutations in the V<sub>H</sub> improving and/or creating dsDNA specificity (clones A and E). Indeed, these two observations provide the first direct evidence of in vivo, stepwise improvements of binding via somatic mutation.

Improvements of DNA binding are correlated with arginine substitutions in at least four sites. Further, although most of the anti-DNAs have an arginine-containing CDR3, the locations of these CDR3 arginine residues are different in each case. Evidently, arginine residues at multiple sites can affect DNA binding. In this regard, DNA may be unlike the hapten nitrophenyl; increased affinity for nitrophenyl is associated with mutation at one recurrent site (60). The variety of sites at which unusual or mutant arginines appear suggests to us that antibody binding of dsDNA may be built up additively in a way reminiscent of antibodies to oligosaccharides (68, 69). For example, it may be that an arginine anywhere in the combining site can contribute to binding. This seems plausible given the polymeric nature of the DNA antigen and the fact that arginine can interact with at least three different groups on DNA (phosphodiester backbone, base-paired guanine, and unpaired and base-paired cytidine) (49, 50), which in turn could be expressed in a variety of conformations (i.e., epitopes).

Implications for Idiotypes

Several groups have produced antiidiotypic antibodies that recognize a majority of anti-DNA in sera of autoimmune mice and humans (70-76). These studies suggested that since a majority of anti-DNA shared a serologically defined similar structure, anti-DNA would be encoded by a restricted set of V genes. However, in three separate cases (42, 77, 78), idiotypes did not correlate with V<sub>H</sub> family when idiotypic positive molecules were sequenced or typed for V<sub>H</sub> family. Our study extends these findings by showing that anti-DNA are not encoded by a restricted set of V genes; even the most frequently expressed V<sub>H</sub> accounts for only 25% of known anti-DNA sequences. It thus seems unlikely that shared idiotypes can be explained by common expression of a V gene. Similarly, it is unlikely that antiidiotypes that recognize the majority of anti-DNA could be "internal images" of DNA (79), because the diverse binding specificities of anti-DNA (57) indicate that there must be many distinct internal images. Thus, the structural explanation for idiotypes lies elsewhere.

We suggest that high arginine content could explain some recurrent antiidiotype systems. For example, arginine-rich CDR3s (or other arginine-rich CDRs) are a feature shared by many anti-DNAs, and these could be recognized by some antiidi-
otypic antibodies. This hypothesis can now be tested by correlating these idiotypes to sequences. In this regard, Eilat et al. (42) recently showed that the Vₙ sequences of two anti-DNAs that share an idiotype differ at V₉ and Vₓ, but have similar, arginine-containing CDR3s.

This comprehensive survey allows us to draw several conclusions about the etiology and genetic basis of anti-DNA in MRL/lpr mice: most or all of the anti-DNA in a given animal are the product of one or a few clonally expanded B cells whose V genes have somatic mutations. The stimulus for this clonal expansion is mediated via the antigen receptor. Combined with the similar results with MRL/lpr-derived RFs, this study shows that antigen-driven clonal expansion is a common feature of humoral autoimmunity in MRL/lpr mice.

B cells in MRL/lpr autoimmunity closely resemble B cells in normal contexts participating in T cell-dependent secondary immune responses (28, 58, 80). It seems likely from this similarity that autoimmune B cell clonal expansion is also dependent on Th cells. This suggests that the primary defect may not be in the B cell per se, but instead, in regulation of the B cell by T cells or T cell–derived factors (e.g., excessive T cell help or absence of T cell suppression). In particular, a search for an activity that facilitates antigen-driven B cell activation should be fruitful.

The antigen stimulus in this case is likely to be DNA, because in two cases affinity for DNA has improved during clonal expansion and evolution. Indeed, in most of the sequences, there is preferential utilization of the amino acid residues expected to play a role in DNA binding. Both these features are unexpected unless DNA itself is the B cell antigen.

Some V genes are found more frequently than expected among antigen-driven anti-DNA, but no V genes or V gene pairs are expressed frequently enough to account for idiotypes expressed on the majority of anti-DNA. This results in a diversity of anti-DNAs sufficient for each individual mouse to have a unique set of anti-DNA clones at any given time. Since the human immune system contains many more cells, such diversity will be recapitulated in a single person. Furthermore, even members of a single clone will differ due to accumulated somatic mutations. These two sources of diversity should make it unlikely that approaches to treatment using antidiotypic antibodies as specific reagents against pathogenic anti-DNA will eliminate a significant proportion of these autoantibodies in any single individual. Two early attempts at this therapy were unsuccessful in achieving long-term suppression of anti-DNA (81, 82). Indeed, even in a monoclonal B cell proliferative disease (follicular lymphoma), the somatic mutation process alone generated sufficient diversity to prevent elimination by antidiotypic antibody therapy (83). However, we do note that anti-DNA Vs are arginine rich, particularly in Vₙ CDR3; we propose that arginines could in part be the ligands for antidiotypic sera. This suggests that a more promising therapy might use smaller aromatic and charged molecules aimed at the building blocks of DNA specificity (e.g., arginines in certain contexts), as has been explored by Ben-Chetrit et al. (84) and Shoajania and Orr (85). Further genetic, functional, and crystallographic analysis of these and similar antibodies and in vitro generated mutants of them will lead to a better understanding of the rules governing antibodies binding to DNA and ultimately the informed design of compounds that might specifically inhibit this interaction.
Summary

The proximate cause of autoantibodies characteristic of systemic autoimmune diseases has been controversial. One hypothesis is that autoantibodies are the result of polyclonal nonspecific B cell activation. Alternatively, autoantibodies could be the result of antigen-driven B cell activation, as observed in secondary immune responses. We have approached this question by studying monoclonal anti-DNA autoantibodies derived from unmanipulated spleen cells of the autoimmune MRL/lpr mouse strain. This analysis shows that anti-DNAs, like rheumatoid factors (19), are the result of specific antigen-driven stimulation. In addition, correlation of sequences with fine specificity shows that: (a) somatic mutations can cause specificity for dsDNA and that such mutations are selected for; (b) arginine residues play an important role in determining specificity; and (c) antiidiotypes that recognize the majority of anti-DNA are probably not specific for any one family of V regions.

Received for publication 10 August 1989 and in revised form 29 September 1989.

References

1. Tan, E. M., P. H. Schur, R. I. Carr, and H. G. Kunkel. 1966. Deoxyribonucleic acid DNA and antibodies to DNA in the serum of patients with systemic lupus erythematosus. J. Clin. Invest. 45:1732.
2. Notman, D. D., N. Kurata, and E. N. Tan. 1974. Profiles of antinuclear antibodies in systemic rheumatic diseases. Ann. Intern. Med. 83:464.
3. Tan, E. M. 1982. Autoantibodies to nuclear antigens (ANA): their immunobiology and medicine. Adv. Immunol. 33:167.
4. Withrington, R. H., I. Teitsson, H. Valdimarsson, and M. Seifert. 1984. Prospective study of early rheumatoid arthritis. II. Association of rheumatoid factor isoatypes with fluctuations in disease activity. Ann. Rheum. Dis. 43:579.
5. Wernick, R., J. J. Lospalluto, C. W. Fink, and M. Ziff. 1981. Serum IgG and IgM rheumatoid factors by solid phase radioimmunoassay. A comparison between adult and juvenile rheumatoid arthritis. Arthritis Rheum. 24:1501.
6. Winfield, J. B., I. Faiferman, and D. Koffler. 1977. Avidity of anti-DNA antibodies in serum and IgG glomerular eluates from patients with systemic lupus erythematosus: association of high avidity anti-native DNA antibody with glomerulonephritis. J. Clin. Invest. 59:90.
7. Datta, S. K., Y. Naparstek, and R. S. Schwartz. 1986. In vitro production of an anti-DNA idiotype by lymphocytes of normal subjects and patients with systemic lupus erythematosus. Clin. Immunol. Immunopathol. 38:302.
8. Panekwycz, O. G., P. Migliorini, and M. Madaio. 1987. Polyreactive autoantibodies are nephritogenic in murine lupus nephritis. J. Immunol. 139:3287.
9. Raz, E., M. Brezis, E. Rosenman, and D. Eliat. 1989. Anti-DNA antibodies bind directly to renal antigens and induce kidney dysfunction in the isolated perfused rat kidney. J. Immunol. 142:3076.
10. Izui, S., V. E. Kelley, K. Masuda, H. Yoshida, J. B. Roths, and E. D. Murphy. 1984. Induction of various autoantibodies by mutant gene lpr in several strains of mice. J. Immunol. 133:227.
11. Kelley, V., and J. B. Roths. 1985. Interaction of mutant lpr gene with background strain influences renal disease. Clin. Immunol. Immunopathol. 37:220.
12. Wolsky, D., R. R. Hardy, and W. E. Seaman. 1984. The proliferating cells in autoim-
mune MRL/lpr mice lack L3T4, an antigen on helper T cells that is involved in the response to Class II major histocompatibility antigens. J. Immunol. 132:2686.

13. Hang, L., A. N. Theofilopoulos, and F. J. Dixon. 1982. A spontaneous rheumatoid arthritis-like disease in MRL/lpr mice. J. Exp. Med. 155:1690.

14. Eisenberg, R. A., E. M. Tan, and F. J. Dixon. 1978. Presence of anti-Sm reactivity in autoimmune mouse strains. J. Exp. Med. 147:582.

15. Pisetsky, D. S., S. A. Caster, J. B. Roths, and E. D. Murphy. 1982. lpr gene control of the anti-DNA response. J. Immunol. 128:2322.

16. Andersson, J., and F. Melchers. 1978. Lymphocyte hybridomas. Curr. Top. Microbiol. Immunol. 81:130.

17. Dildrop, R., U. Krawinkel, E. Winter, and K. Rajewsky. 1985. Vα gene expression in murine lipopolysaccharide blasts distributes over the nine known Vα groups and may be random. Eur. J. Immunol. 15:1154.

18. Shlomchik, M., D. Nemazee, J. Van Snick, and M. Weigert. 1987. Variable region sequences of murine IgM anti-IgG monoclonal autoantibodies rheumatoid factors. II. Comparison of hybridomas derived by lipopolysaccharide stimulation and secondary protein immunization. J. Exp. Med. 165:970.

19. Shlomchik, M. J., A. Marshak-Rothstein, C. B. Wolfowicz, T. L. Rothstein, and M. G. Weigert. 1987. The role of clonal selection and somatic mutation in autoimmunity. Nature (Lond.) 328:805.

20. Shlomchik, M. J., A. H. Aucoin, D. S. Pisetsky, and M. G. Weigert. 1987. Structure and function of anti-DNA autoantibodies derived from a single autoimmune mouse. Proc. Natl. Acad. Sci. USA. 84:9150.

21. Pisetsky, D. S., and K. F. Semper. 1984. Influence of assay conditions on ELISAS determinations of anti-DNA antibodies. J. Immunol. Methods. 74:217.

22. Marshak-Rothstein, A., P. Fink, T. Gridley, D. H. Raulet, M. J. Bevan, and M. L. Gefter. 1979. Properties and applications of monoclonal antibodies directed against determinants of the Thy-1 locus. J. Immunol. 133:2491.

23. Oi, V. T., and L. A. Herzenberg. 1980. Immunoglobulin producing hybrid cell lines. In Selected Methods in Cellular Immunology. B. B. Mishell, and S. M. Shiigi, editors. W. H. Freeman, San Francisco. 351–372.

24. Pisetsky, D. S., and D. V. Peters. 1982. A simple enzyme-linked immunosorbent assay for antibodies to native DNA. J. Immunol. Methods. 41:187.

25. Morse, H. C., R. Riblet, R. Asofsky, and M. Weigert. 1978. Plasmacytomas of the NZB mouse. J. Immunol. 121:1969.

26. Eaton, R. B., G. Schneider, and P. H. Schur. 1983. Enzyme immunoassay for antibodies to native DNA. Specificity and quality of antibodies. Arthritis Rheum. 26:1:52.

27. Stollar, B. D., G. Zon, and R. W. Pastor. 1986. A recognition site on synthetic helical oligonucleotides for monoclonal anti-native DNA antibody. Proc. Natl. Acad. Sci. USA. 83:4469.

28. Clarke, S., K. Huppi, D. Ruezinsky, L. Staadt, W. Gerhard, and M. G. Weigert. 1985. Inter- and intraclonal diversity in the antibody response to influenza hemagglutinin. J. Exp. Med. 161:687.

29. Shlomchik, M. J., D. Nemazee, V. Sato, J. Van Snick, D. Carson, and M. G. Weigert. 1986. Variable region sequences of murine IgM Anti-IgG monoclonal autoantibodies rheumatoid factors: a structural explanation for the high frequency of IgM Anti-IgG B cells. J. Exp. Med. 164:407.

30. Geliebter, J., R. A. Zeff, R. W. Meldold, and S. G. Nathenson. 1986. Mitotic recombination in germ cells generated two major histocompatibility mutant genes shown to be identical by RNA sequence analysis: Kb and Kb. Proc. Natl. Acad. Sci. USA. 83:3371.
31. Alt, F., and D. Baltimore. 1982. Joining of immunoglobulin heavy chain gene segments: implications from a chromosome with evidence of three D-Jb fusions. Proc. Natl. Acad. Sci. USA. 79:4118.
32. Wysocki, L., T. Manser, and M. Gefter. 1986. Somatic evolution of variable region structures during an immune response. Proc. Natl. Acad. Sci. USA. 83:1847.
33. Brodeur, P., and R. Riblet. 1984. The immunoglobulin heavy chain variable region in the mouse I. 100 IgH-V genes comprise 7 families of homologous genes. Eur. J. Immunol. 14:922.
34. Winter, E., A. Radbruch, and U. Krawinkel. 1985. Members of novel V\textsubscript{\alpha} families are found in VDJ regions of polyclonally activated B-lymphocytes. EMBO (Eur. Mol. Biol. Organ.) J. 4:2861.
35. Kofler, R. 1988. A new murine Ig V\textsubscript{\alpha} gene family. J. Immunol. 140:4031.
36. Kofler, R., R. Strohal, R. S. Balderas, M. E. Johnson, D. J. Noonan, M. A. Duchosal, F. J. Dixon, and A. N. Theofilopoulos. 1988. Immunoglobulin κ light chain variable region gene complex organization and immunoglobulin genes encoding anti-DNA autoantibodies in lupus mice. J. Clin. Inherit. 82:852.
37. Reininger, L., A. Kaushik, S. Izui, and J.-C. Jaton. 1988. A member of a new V\textsubscript{\alpha} gene family encodes anti-bromelinized mouse red blood cell autoantibodies. Eur. J. Immunol. 18:1521.
38. Pennell, C. A., L. W. Arnold, G. Haughton, and S. H. Clarke. 1988. Restricted Ig variable region gene expression among Ly-1\textsuperscript{+} B cell lymphomas. J. Immunol. 141:2788.
39. Potter, M., J. B. Newell, S. Rudikoff, and E. Haber. 1982. Classification of mouse V\textsubscript{\kappa} groups based on the partial amino acid sequence to the first invariant tryptophan: impact of 14 new sequences from IgG myeloma proteins. Mol. Immunol. 19:1619.
40. D’Hoostelaere, L., K. Huppi, B. Mock, C. Mallett, D. Gibson, J. Hilgers, and M. Potter. 1988. The organization of the immunoglobulin kappa locus in mice. Curr. Top. Microbiol. Immunol. 137:116.
41. Trepicchio, W., A. Maruya, and K. J. Barrett. 1987. The heavy chain genes of a lupus anti-DNA autoantibody are encoded in the germ line of a nonautoimmune strain of mouse and conserved in strains of mice polymorphic for this gene locus. J. Immunol. 139:3139.
42. Eilat, D., D. M. Webster, and A. R. Rees. 1988. V region sequences of anti-DNA and anti-RNA autoantibodies from NZB/NZW F\textsubscript{1} mice. J. Immunol. 141:1745.
43. Maizels, N., and A. Bothwell. 1985. The T-cell-independent immune response to the hapten NP uses a large repertoire of heavy chain genes. Cell. 49:715.
44. Kabat, E. A., T. T. Wu, M. Reid-Miller, H. M. Perry, and K. S. Gottesman. 1987. Sequences of proteins of immunological interest. U. S. Government Printing Office, Bethesda, MD.
45. Kaartinen, M., and O. Mäkelä. 1985. Reading of D genes in variable frames as a source of antibody diversity. Immumol. Today. 6:324.
46. Kurosawa, Y., and S. Tonegawa. 1982. Organization, structure, and assembly of immunoglobulin heavy chain diversity DNA segments. J. Exp. Med. 155:201.
47. Meek, K., C. Hasemann, B. Pollok, S. S. Alkan, M. Brait, M. Slaoui, J. Urbain, and J. D. Capra. 1989. Structural characterization of antiidiotypic antibodies. J. Exp. Med. 169:519.
48. Ollier, P. J., G. Rocca-Serra, J. Somme, J. Theze, and M. Fougereau. 1985. The idiotype network and internal image: Possible regulation of a germline network by paucigene encoded Ab2 anti-idiotypic antibodies in the GAT system. EMBO (Eur. Mol. Biol. Organ.) J. 4:3681.
49. Seeman, N. C., J. M. Rosenberg, and A. Rich. 1976. Sequence-specific recognition of double helical nucleic acids by proteins. Proc. Natl. Acad. Sci. USA. 73:804.
50. McClarin, J. A., C. A. Frederick, B. Wang, P. Greene, H. W. Boyer, J. Grable, and J. M. Rosenberg. 1986. Structure of the DNA-Eco RI endonuclease recognition complex at 3Å resolution. *Science* (Washington, DC). 234:1526.

51. Furukawa, F., H. Tanaka, K. Sekita, T. Nakamura, Y. Horiguchi, and Y. Hamashima. 1984. Dermatopathological studies on skin lesions of MRL mice. *Arch. Dermatol. Res.* 276:186.

52. Wolfowicz, C. B., P. Sakorasas, T. L. Rothstein, and A. Marchak-Rothstein. 1988. Oligoclonality of rheumatoid factors arising spontaneously in lpr/lpr mice. *Clin. Immunol. Immunopathol.* 46:382.

53. Van Snick, J., and P. Coulie. 1983. Rheumatoid factors and secondary immune responses in the mouse I. Frequent occurrence of hybridomas secreting IgM anti-IgG1 autoantibodies after immunization with protein antigens. *Eur. J. Immunol.* 13:890.

54. Souroujon, M., M. E. White-Scharf, J. Andre-Schwartz, M. L. Gefter, and R. S. Schwartz. 1988. Preferential autoantibody reactivity of the preimmune B cell repertoire in normal mice. *J. Immunol.* 140:4173.

55. Conger, J. D., B. L. Pike, and G. J. V. Nossal. 1987. Clonal analysis of the anti-DNA repertoire of murine B lymphocytes. *Proc. Natl. Acad. Sci. USA.* 84:2931.

56. Rolink, A. G., Radazekiewicz, and F. Melchers. 1987. The autoantigen-binding B cell repertoires of normal and of chronically graft-versus-host-diseased mice. *J. Exp. Med.* 165:1675.

57. Andrezejewski, C., J. Rauch, E. Lafer, B. D. Stollar, and R. S. Schwartz. 1981. Antigen-binding diversity and idioypical cross-reactions among hybridoma autoantibodies to DNA. *J. Immunol.* 126:226.

58. Blier, P. R., and A. Bothwell. 1987. A limited number of B cell lineages generate the heterogeneity of a secondary immune response. *J. Immunol.* 139:3996.

59. Berek, C., G. M. Griffiths, and C. Milstein. 1985. Molecular events during maturation of the immune response to oxazolone. *Nature* (London). 316:412.

60. Allen, D., T. Simon, F. Sablitzy, K. Rajewsky, and A. Curnan. 1988. Antibody engineering for the analysis of affinity maturation of an anti-hapten response. *EMBO (Eur. Mol. Biol. Organ.)* J. 7:1995.

61. Rappard-Van Der Veen, F. M., V. Kiesel, L. Poels, W. Schuler, C. J. M. Melief, J. Laugdent, and E. Gleichmann. 1984. Further evidence against random polyclonal antibody formation in mice with lupus-like graft-vs-host disease. *J. Immunol.* 132:1814.

62. Portanova, J. P., J. N. Claman, and B. L. Kotzin. 1985. Autoimmunization in murine graft-vs-host disease. I. Selective production of antibodies to histones and DNA. *J. Immunol.* 135:3850.

63. Hardin, J. A. 1986. The lupus autoantigens and pathogenesis of systemic lupus erythematosus. *Arthritis Rheum.* 29:457.

64. Dildrop, R. 1984. A new classification of mouse V\(_\alpha\) sequences. *Immunology Today.* 5:85.

65. Schiiff, C., S. Corbet, and M. Fougereau. 1988. The Ig germline repertoire: economy or wastage? *Immunol. Today.* 9:10.

66. Klinman, D. M., and A. D. Steinberg. 1987. Systemic autoimmune disease arises from polyclonal B cell activation. *J. Exp. Med.* 165:1755.

67. Ishigatsubo, Y., A. D. Steinberg, and D. M. Klinman. 1988. Autoantibody production is associated with polyclonal B cell activation in autoimmune mice which express the lpr or gld genes. *Eur. J. Immunol.* 18:1089.

68. Kabat, E. A. 1956. Heterogeneity in extent of the combining regions of human antidextran. *J. Immunol.* 77:377.

69. Wu, A. M., E. A. Kabat, and M. Weigert. 1978. Immunochemical studies of dextran-specific and levan-specific myeloma proteins from NZB mice. *Carbohydr. Res.* 66:113.

70. Rauch, J., E. Murphy, J. B. Roths, B. D. Stollar, and R. S. Schwartz. 1982. A high fre-
frequency idiotypic marker of anti-DNA autoantibodies in MRL-lpr/lpr mice. J. Immunol. 129:236.
71. Marion, T. N., A. R. Lawton, J. F. Kearney, and D. E. Briles. 1982. Anti-DNA autoantibodies in NZB × NZW F1 mice are clonally heterogeneous but the majority share a common idiotype. J. Immunol. 128:668.
72. Eilat, D., R. Fischel, and A. Zlotnik. 1985. A central anti-DNA idiotype in human and murine systemic lupus erythematosus. Eur. J. Immunol. 15:368-375.
73. Hahn, B. H., and F. M. Ebhing. 1987. Idiotype restriction in murine lupus: high frequency of three public idiotypes on serum IgG in nephritic NZB/NZW F1 mice. J. Immunol. 138:2110.
74. Solomon, G., J. Schiffernauer, H. D. Keiser, and B. Diamond. 1982. Use of monoclonal antibodies to identify shared idiotypes on human antibodies to native DNA from patients with systemic lupus erythematosus. Proc. Natl. Acad. Sci. USA. 80:850.
75. Shoenfeld, Y., D. A. Isenberg, J. Rauch, M. Madaio, B. D. Stollar, and R. S. Schwartz. 1983. Idiotypic crossreactions of monoclonal human lupus autoantibodies. J. Exp. Med. 158:718.
76. Gavalchien, J., and S. K. Datta. 1987. The NZB/SWR model of lupus nephritis. Autoantibody deposited in renal lesions show a restricted idiotypic diversity. J. Immunol. 138:138.
77. Trepcicchio, W., and K. J. Barrett. 1987. Eleven MRL-lpr/lpr anti-DNA autoantibodies are encoded by genes from four \( V_\alpha \) gene families: a potentially biased usage of \( V_\alpha \) genes. J. Immunol. 138:2323.
78. Marion, T. N., A. L. M. Bothwell, D. G. Briles, and C. A. Janeway. 1989. IgG anti-DNA autoantibodies within the idiotype mouse are the products of clonal selection. J. Immunol. 142:4269.
79. Jerne, N. K. 1974. Toward a network theory of the immune system. Ann. Immunol. (Paris). 1256:373.
80. Sablitzky, F., G. Wildner, and K. Rajewsky. 1985. Somatic mutation and clonal expansion of B cells in an antigen-driven immune response. EMBO (Eur. Mol. Biol. Organ.) J. 4:345.
81. Hahn, B. H., and F. M. Ebhing. 1984. Suppression of murine lupus nephritis by administration of an anti-idiotype antibody to anti-DNA. J. Immunol. 132:187.
82. Teitelbaum, D., J. Rauch, B. D. Stollar, and R. S. Schwartz. 1984. In vivo effects of antibodies against a high frequency idiotype of anti-DNA antibodies in MRL mice. J. Immunol. 123:1282.
83. Cleary, M. L., T. C. Meeker, S. Levy, E. Lee, M. Trela, J. Sklar, and R. Levy. 1986. Clustering of extensive somatic mutations in the variable region of an immunoglobulin heavy chain gene from a human B cell lymphoma. Cell. 44:97.
84. Ben-Chetrit, E., D. Eilat, and S. A. Ben-Sasson. 1988. Specific inhibition of the DNA anti-DNA immune reaction by low molecular weight anionic compounds. Immunology. 65:479.
85. Shojaania, A. M., and K. Orr. 1987. The effect of toluidine blue and methylene blue in immunochemical reactions in vitro. Clin. Immunol. Immunopath. 43:223.
86. Graybill, F. A. 1976. Theory and Application of the Linear Model. Dixburg Press, North Scituate, MA.
87. Loh, D. Y., A. L. M. Bothwell, M. E. White-Scharf, T. Imanishi-Kari, and D. Baltimore. 1983. Molecular basis of a mouse strain-specific anti-hapten response. Cell. 33:85-93.
88. Ollo, R., J.-L. Sikorav, and F. Rougeon. 1983. Structural relationships among mouse and human immunoglobulin \( V_\alpha \) genes in the subgroup III. Nucleic Acids Res. 11:7887.
89. Clarke, S. H., J. L. Claffin, and S. Rudikoff. 1982. Polymorphisms in immunoglobulin heavy chain genes suggesting gene conversion. Proc. Natl. Acad. Sci. USA. 79:3280.
90. Liu, A. Y., R. R. Robinson, K. E. Hellstrom, E. D. Murray, P. Chang, and I. Hellstrom. 1987. Chimeric mouse-human IgG1 antibody that can mediate lysis of cancer cells. Proc. Natl. Acad. Sci. USA. 84:3439.

91. Corbet, S., M. Milili, M. Fougereau, and C. Schiff. 1987. Two $V_e$ germ-line genes related to the GAT idiotypic network Ab1 and Ab3/Ab1' account for the major subfamilies of the mouse $V_e$-I subgroup. J. Immunol. 138:932.

92. Queen, C., and D. Baltimore. 1983. Immunoglobulin gene transcription is activated by down-stream sequence elements. Cell. 33:741.